An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Xospata

Chemical Namegilteritinib
Dosage FormTablet (oral; 40 mg)
Drug ClassKinase inhibitors
SystemBlood
CompanyAstellas Pharma Inc.
Approval Year2018

Indication

  • To treat refractory or relapsed acute myeloid leukemia in adults with a FLT3 mutation.
Last updated on 3/10/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Xospata (Gilteritinib) Prescribing Information 2018Astellas Pharma US, Inc, Northbrook, IL
Document TitleYearSource
Gilteritinib for treating relapsed or refractory acute myeloid leukaemia. 2020NICE
Pharmacoeconomic report: Gilteritinib (xospata).2020CADTH